Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1978 1
1988 1
1997 1
2000 1
2002 1
2003 4
2005 6
2006 7
2007 4
2008 6
2009 4
2010 7
2011 3
2012 9
2013 13
2014 14
2015 13
2016 10
2017 13
2018 8
2019 4
2020 5
2021 5
2022 8
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
The role of BRAF V600 mutation in melanoma.
Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. Ascierto PA, et al. Among authors: simeone e. J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85. J Transl Med. 2012. PMID: 22554099 Free PMC article.
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA. Capone M, et al. Among authors: simeone e. J Immunother Cancer. 2018 Jul 16;6(1):74. doi: 10.1186/s40425-018-0383-1. J Immunother Cancer. 2018. PMID: 30012216 Free PMC article.
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.
Mallardo D, Simeone E, Festino L, Tuffanelli M, Vanella V, Trojaniello C, Vitale MG, Ottaviano M, Capone M, Madonna G, Sparano F, Cioli E, Scarpato L, Palla M, Di Trolio R, Meinardi P, Caracò C, Ferrara G, Muto P, Cavalcanti E, Ascierto PA. Mallardo D, et al. Among authors: simeone e. J Transl Med. 2023 Feb 23;21(1):140. doi: 10.1186/s12967-023-03971-5. J Transl Med. 2023. PMID: 36823670 Free PMC article.
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy.
Mallardo D, Fordellone M, White A, Ottaviano M, Sparano F, Bailey M, Facchini AB, Ong S, Maiolino P, Caracò C, Church S, Cavalcanti E, Warren S, Budillon A, Cesano A, Simeone E, Chiodini P, Ascierto PA. Mallardo D, et al. Among authors: simeone e. J Transl Med. 2023 Sep 8;21(1):610. doi: 10.1186/s12967-023-04419-6. J Transl Med. 2023. PMID: 37684649 Free PMC article.
Immunotherapy Assessment: A New Paradigm for Radiologists.
Granata V, Fusco R, Setola SV, Simonetti I, Picone C, Simeone E, Festino L, Vanella V, Vitale MG, Montanino A, Morabito A, Izzo F, Ascierto PA, Petrillo A. Granata V, et al. Among authors: simeone e. Diagnostics (Basel). 2023 Jan 13;13(2):302. doi: 10.3390/diagnostics13020302. Diagnostics (Basel). 2023. PMID: 36673112 Free PMC article. Review.
Anti-PD-1 and PD-L1 antibodies in metastatic melanoma.
Simeone E, Ascierto PA. Simeone E, et al. Melanoma Manag. 2017 Dec;4(4):175-178. doi: 10.2217/mmt-2017-0018. Epub 2017 Nov 21. Melanoma Manag. 2017. PMID: 30190923 Free PMC article. No abstract available.
BRAF Gene and Melanoma: Back to the Future.
Ottaviano M, Giunta EF, Tortora M, Curvietto M, Attademo L, Bosso D, Cardalesi C, Rosanova M, De Placido P, Pietroluongo E, Riccio V, Mucci B, Parola S, Vitale MG, Palmieri G, Daniele B, Simeone E, On Behalf Of Scito Youth. Ottaviano M, et al. Among authors: simeone e. Int J Mol Sci. 2021 Mar 27;22(7):3474. doi: 10.3390/ijms22073474. Int J Mol Sci. 2021. PMID: 33801689 Free PMC article. Review.
Marker utility for combination therapy.
Simeone E, Grimaldi AM, Ascierto PA. Simeone E, et al. Methods Mol Biol. 2014;1102:97-115. doi: 10.1007/978-1-62703-727-3_7. Methods Mol Biol. 2014. PMID: 24258976 Review.
PD-L1 inhibitors in the pipeline: Promise and progress.
Vanella V, Festino L, Strudel M, Simeone E, Grimaldi AM, Ascierto PA. Vanella V, et al. Among authors: simeone e. Oncoimmunology. 2017 Sep 21;7(1):e1365209. doi: 10.1080/2162402X.2017.1365209. eCollection 2017. Oncoimmunology. 2017. PMID: 29296516 Free PMC article. Review.
140 results